reports
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera’s new Chief Legal Officer, under Vera’s 2024 Inducement Plan. The Compensation Committee approved the a...
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. “We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and...
Akero Therapeutics to Present at the Jefferies London Healthcare Confe...
Akero Therapeutics to Present at the Jefferies London Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT. A live webcast of the Company presentation will be available through the investor relations section of the...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in ...
Vera Therapeutics Partners with University of Michigan on the NEPTUNE ...
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands the investigation of atacicept into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; BRISBANE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company fo...
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1sWebcast: Date:...
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1sWebcast: Date: Wednesd...
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Pr...
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update — First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027 — — Phase 2b SYMMETRY study week 96 results expected to readout in February 2025 — SOUTH SAN FRANCISCO, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cl...
- Wedbush Research
GEO GEO GROUP INC. (THE)
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
TSLA TESLA INC
SAGE SAGE THERAPEUTICS INC.
RNG RINGCENTRAL INC. CLASS A
PZZA PAPA JOHN'S INTERNATIONAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
LOW LOWE'S COMPANIES INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
FTNT FORTINET INC.
EXPE EXPEDIA GROUP INC.
CXW CORECIVIC INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
PTGX PROTAGONIST THERAPEUTICS
RDFN REDFIN CORPORATION
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
HEAR TURTLE BEACH CORP.
RH RESTORATION HARDWARE INC.
PINS PINTEREST INC. CLASS A
GOSS GOSSAMER BIO
STOK STOKE THERAPEUTICS
DT DYNATRACE INC.
DDOG DATADOG INC CLASS A
APRE APREA THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
U UNITY SOFTWARE
RZLT REZOLUTE
ABNB AIRBNB INC. CLASS A
PLTR PALANTIR TECHNOLOGIES
VOR VOR BIOPHARMA
BUR BURFORD CAPITAL
CGEM CULLINAN ONCOLOGY INC
UPST UPSTART HOLDINGS
LBPH LONGBOARD PHARMACEUTICALS
VERA VERA THERAPEUTICS INC
TTD THE TRADE DESK
GLUE INC.
ARHS MONTE ROSA THERAPEUTICS INC
CCSI ARHAUS INC
RIVN CONSENSUS CLOUD SOLUTIONS INC
VIGL RIVIAN AUTOMOTIVE INC
PEPG VIGIL NEUROSCIENCE INC
TOST PEPGEN INC
EWTX TOAST INC
GETY EDGEWISE THERAPEUTICS INC
SKLZ GETTY IMAGES HOLDINGS INC
DNTH SKILLZ INC
CRBP DIANTHUS THERAPEUTICS INC
SYRE CORBUS PHARMACEUTICALS HOLDINGS INC.
SPYRE THERAPEUTICS INC.
- Dylan Shindler
- Laura Chico
Vera Therapeutics Provides Business Update and Reports Third Quarter 2...
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 with simultaneous peer-reviewed publication in the Journal of the American Society of Nephrology (JASN)Completed enrollment of the primary endpoint cohort in the pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN; topline data expected in Q2 2025Announced expanded atacicept development prog...
Vera Therapeutics Announces Pricing of Public Offering of Class A Comm...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and estima...
Vera Therapeutics Announces Proposed Public Offering of Class A Common...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300.0 million of shares of its Class A common stock. All of the shares are being offered by Vera. In connection with the proposed offering, Vera expects to...
- Wedbush Research
GEO GEO GROUP INC. (THE)
UBI UBISOFT ENTERTAINMENT SA
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
CXW CORECIVIC INC.
CPT CAMDEN PROPERTY TRUST
BPMC BLUEPRINT MEDICINES CORP.
BIIB BIOGEN INC.
ARDX ARDELYX INC
HST HOST HOTELS & RESORTS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
SAFE SAFEHOLD INC.
SMCI SUPER MICRO COMPUTER
IDYA INC.
TVTX IDEAYA BIOSCIENCES
RBLX TRAVERE THERAPEUTICS INC
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
VERA INC
SEAGATE TECHNOLOGY HLDGS PLC
VERA THERAPEUTICS INC
- Laura Chico
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase...
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN Phase 2b study were simultaneously published in the Journal of the American Society of Nephrology;Company will host an investor call and webcast on Monday October 28 at 8:00 AM ET BRISBANE, Calif., O...
QNB Corp. Reports Earnings for Third Quarter 2024
QNB Corp. Reports Earnings for Third Quarter 2024 QUAKERTOWN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- QNB Corp. (the “Company” or “QNB”) (OTC Bulletin Board: QNBC), the parent company of QNB Bank (the “Bank”), reported net income for the third quarter of 2024 of $3,338,000, or $0.91 per share on a diluted basis. This compares to net income of $2,344,000, or $0.65 per share on a diluted basis, for the same period in 2023. For the nine months ended September 30, 2024, QNB reported net income of $8,397,000, or $2.29 per share on a diluted basis. This compares to net income of $8,349,000, or $...
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxif...
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15...
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 125,000 shares of Class A common stock and restricted stock units (RSUs) for 62,500 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.